Drug development: how academia, industry and authorities interact

Area of Science:

• Nephrology
• Clinical Trials
• Drug Development

Background:

• Current drug development paradigms exhibit numerous pitfalls, especially in the design, conduct, and evaluation of Phase III clinical trials.
• Specific challenges in nephrology clinical trials include inappropriate placebo use, biased reporting of results, questionable guideline impartiality, and insufficient elderly patient recruitment.

Approach:

• This perspectives article critically examines existing flaws within the drug development process.
• It proposes actionable improvements to legislation and trial methodologies.

Key Points:

• Inappropriate placebo use in clinical trials.
• Publication bias favoring treatment benefits over adverse events.
• Impartiality concerns with independent clinical guidelines.
• Inadequate recruitment of elderly populations in trials.

Conclusions:

• The current drug development process requires significant reform to ensure patient safety and effective drug evaluation.
• Suggested improvements aim to balance academic, patient, and pharmaceutical industry requirements.
• Legislative and procedural enhancements are proposed to align public needs with commercial objectives.